touchINFECTIOUS DISEASES caught up with Larry Corey (Fred Hutchinson Cancer Research Center, Seattle, WA, US) to discuss VRC01 antibody prevention of HIV, and results from the AMP study.
The abstract entitled: ‘VRC01 antibody prevention of HIV’ (HY01.01LB) was presented at the HIVR4P Virtual Conference 2021, 27 January 2021.
- What is the rationale for the use of the VRC01 antibody in the prevention of HIV?
- What are the challenges in the use of broadly neutralizing antibodies in this indication, and how have they been overcome?
- How does VRC01 prevention efficacy vary with HIV-1 envelope amino acid sequence features?
- What is the status of research into other broadly neutralizing antibodies in the prevention of HIV?
Disclosures: Larry Corey has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of HIVR4P Virtual Conference 2021.
Share this Video
Related Videos In HIV
Lulu Nair, IAS 2021: The Health Burden of HIV among Young Women in Africa
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the the health burden of HIV among young women and adolescent girls in Africa, and the need for pre-exposure prophylaxis. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in […]
Lulu Nair, IAS 2021: Interim results from the REACH study
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the interim results from the REACH study. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study’ was presented at IAS 2021 – […]
Sara Bares, ACTIV 2021: Long-acting Injectable Antiretroviral Therapy for the Treatment of HIV
It was a pleasure to speak with Sara Bares (University of Nebraska, Omaha, NE, USA) to discuss long-acting injectable antiretroviral therapies for the treatment of HIV. The abstract entitled: ‘Long Acting ART for Treatment of HIV’ was presented at the ACTHIV Virtual Conference 2021, May 20-22, 2021. Questions: What are the potential advantages and disadvantages […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!